Selected research
Industry Research
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Research Report 2026
Market perspective
The global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine include Boehringer Ingelheim, Ceva, Merck, Pharmgate, Zoetis, SPAH, Huizhong Biological, Jiangsu Nannong Hi-Tech and Jinyu Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Company
Boehringer Ingelheim
Ceva
Merck
Pharmgate
Zoetis
SPAH
Huizhong Biological
Jiangsu Nannong Hi-Tech
Jinyu Biotechnology
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Type
One-dose Type
Two-dose Type
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Application
Piglet
Adult Pig
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- One-dose Type
- Two-dose Type
Applications
- Piglet
- Adult Pig
Companies covered
- Boehringer Ingelheim
- Ceva
- Merck
- Pharmgate
- Zoetis
- SPAH
- Huizhong Biological
- Jiangsu Nannong Hi-Tech
- Jinyu Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size (2021-2032)
- 2.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (2021-2032)
- 2.2.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Average Price (2021-2032)
- 2.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 One-dose Type
- 2.3.3 Two-dose Type
- 2.4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Piglet
- 2.4.3 Adult Pig
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine, Established Date
- 3.9 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Ceva
- 4.2.1 Ceva Company Information
- 4.2.2 Ceva Business Overview
- 4.2.3 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.2.5 Ceva Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Pharmgate
- 4.4.1 Pharmgate Company Information
- 4.4.2 Pharmgate Business Overview
- 4.4.3 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.4.5 Pharmgate Recent Developments
- 4.5 Zoetis
- 4.5.1 Zoetis Company Information
- 4.5.2 Zoetis Business Overview
- 4.5.3 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.5.5 Zoetis Recent Developments
- 4.6 SPAH
- 4.6.1 SPAH Company Information
- 4.6.2 SPAH Business Overview
- 4.6.3 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.6.5 SPAH Recent Developments
- 4.7 Huizhong Biological
- 4.7.1 Huizhong Biological Company Information
- 4.7.2 Huizhong Biological Business Overview
- 4.7.3 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.7.5 Huizhong Biological Recent Developments
- 4.8 Jiangsu Nannong Hi-Tech
- 4.8.1 Jiangsu Nannong Hi-Tech Company Information
- 4.8.2 Jiangsu Nannong Hi-Tech Business Overview
- 4.8.3 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.8.5 Jiangsu Nannong Hi-Tech Recent Developments
- 4.9 Jinyu Biotechnology
- 4.9.1 Jinyu Biotechnology Company Information
- 4.9.2 Jinyu Biotechnology Business Overview
- 4.9.3 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
- 4.9.5 Jinyu Biotechnology Recent Developments
5 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Scenario by Region
- 5.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2027-2032
- 5.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2027-2032
- 5.4 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
- 5.4.1 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
- 5.7.1 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Value Chain Analysis
- 8.1.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Production Mode & Process
- 8.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Distributors
- 8.2.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Customers
9 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Analyzing Market Dynamics
- 9.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Trends
- 9.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Drivers
- 9.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Opportunities and Challenges
- 9.4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst